Literature DB >> 14660597

Geldanamycin-associated inhibition of intracellular trafficking is attributed to a co-purified activity.

Eran Barzilay1, Nathalie Ben-Califa, Lia Supino-Rosin, Yoel Kashman, Koret Hirschberg, Zvulun Elazar, Drorit Neumann.   

Abstract

Geldanamycin, an ansamycin antibiotic that specifically inhibits heat-shock protein-90 (HSP90) and its endoplasmic reticulum homologue, glucose-regulated protein-94 (GRP94), accelerates the degradation of selected cellular proteins. We showed previously that geldanamycin inhibits maturation and transport of the epidermal growth factor receptor in addition to accelerating its degradation (Supino-Rosin, L., Yoshimura, A., Yarden, Y., Elazar, Z., and Neumann, D. (2000) J. Biol. Chem. 275, 21850-21855). Here we demonstrate that the additional activities of geldanamycin on intracellular transport and protein maturation are related to its supply source. By combining chemical separation of Streptomyces hygroscopicus var. geldanus extracts and biological screens, we show that the geldanamycin-associated effects on intracellular transport and protein maturation are not mediated by geldanamycin itself but are due to the presence of an additional component(s). Chromatography of S. hygroscopicus var. geldanus extracts on a silica-gel column allowed separation between the inhibition of intracellular trafficking and geldanamycin-mediated degradation. One fraction that was devoid of geldanamycin blocked secretion of a soluble form of the erythropoietin receptor, retarded maturation of the epidermal growth factor receptor without enhancing its degradation, and blocked anterograde transport of a temperature-sensitive mutant of the vesicular stomatitis virus G protein (VSVGtsO45) from the early Golgi cisternae. This fraction was enriched (>95%) in 17-demethylgeldanamycin. However, as synthetically derived 17-demethylgeldanamycin did not inhibit intracellular trafficking, we concluded that 17-demethylgeldanamycin is not the active component. We thus propose that a compound(s) that co-purifies with benzoquinone ansamycins inhibits intracellular transport. Taken together, our data demonstrate that the inhibitory effects on protein maturation and intracellular trafficking, previously attributed to geldanamycin, are mediated by another distinct moiety.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660597     DOI: 10.1074/jbc.M312799200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses.

Authors:  John H Connor; Margie O McKenzie; Griffith D Parks; Douglas S Lyles
Journal:  Virology       Date:  2007-01-26       Impact factor: 3.616

2.  Natalamycin A, an Ansamycin from a Termite-Associated Streptomyces sp.

Authors:  Ki Hyun Kim; Timothy R Ramadhar; Christine Beemelmanns; Shugeng Cao; Michael Poulsen; Cameron R Currie; Jon Clardy
Journal:  Chem Sci       Date:  2014-11-01       Impact factor: 9.825

3.  HSP90 inhibitor geldanamycin reverts IL-13- and IL-17-induced airway goblet cell metaplasia.

Authors:  Alejandro A Pezzulo; Rosarie A Tudas; Carley G Stewart; Luis G Vargas Buonfiglio; Brian D Lindsay; Peter J Taft; Nicholas D Gansemer; Joseph Zabner
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

4.  Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.

Authors:  Gang Niu; Zibo Li; Qizhen Cao; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-14       Impact factor: 9.236

5.  Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor.

Authors:  Gang Niu; Weibo Cai; Kai Chen; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2007-12-22       Impact factor: 3.488

6.  An extracellular region of the erythropoietin receptor of the subterranean blind mole rat Spalax enhances receptor maturation.

Authors:  Orly Ravid; Imad Shams; Nathalie Ben Califa; Eviatar Nevo; Aaron Avivi; Drorit Neumann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-27       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.